STOCK TITAN

Replimune to Present at Three Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Replimune Group, Inc. announces participation in three upcoming investor conferences to present oncolytic immunotherapies.
Positive
  • None.
Negative
  • None.

WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following three conferences:

Leerink Partners 2024 Global Biopharma Conference
Date: Tuesday, March 12, 2024
Fireside Chat Time: 2:20 pm EDT

Jefferies Biotech on the Bay Miami Summit
Date: Wednesday, March 13, 2024

Barclays 26th Annual Global Healthcare Conference
Date: Thursday, March 14, 2024
Fireside Chat Time: 10:45 am EDT

Live webcasts of the Leerink and Barclays fireside chats will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for 30 days following the conference.

About Replimune 
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com


FAQ

When will Replimune Group, Inc. present at the Leerink Partners 2024 Global Biopharma Conference?

Replimune Group, Inc. will present at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024, at 2:20 pm EDT.

Where can investors watch the live webcasts of the Leerink and Barclays fireside chats?

Investors can watch the live webcasts of the Leerink and Barclays fireside chats on Replimune's website at www.replimune.com.

How long will the replay be available for the conference webcasts?

The replay of the conference webcasts will be available for 30 days following the conferences.

Replimune Group, Inc.

NASDAQ:REPL

REPL Rankings

REPL Latest News

REPL Stock Data

426.65M
39.05M
5.8%
113.16%
12.6%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WOBURN

About REPL

replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.